Cottage Center for Orthopedics Helps Gary Enjoy an Active Life Again

(44)

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

(1:39)

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

(1:3)

Dr. Hurvitz on Patient Outcomes and PIK3CA Mutations

(1:59)

Dr. Hurvitz on Therapeutics for HER2+ Metastatic Breast Cancer

(1:35)

Dr. Hurvitz on the Impact of Biosimilars

(1:38)

Dr. Hurvitz on Novel Agents in HER2-Positive Breast Cancer

(2:3)

Dr. Hurvitz Discusses De-Escalation in HER2+ Breast Cancer

(1:27)

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

(58)

CDK 4/6 Inhibitors in Breast Cancer Advanced and Adjuvant Settings

(26:34)

Dr. Eric C. Leuthardt Installation Video

(1:7:54)

SickKids $50 Million Gift Announcement

(52:31)

HER2-Positive Breast Cancer—Reduce Your Risk of Recurrence | Access Health

(20:11)

Anti-HER2 Mechanisms of Approved HER2 Inhibitors

(5:5)

Grip Strength and Body Composition in Cerebral Palsy Webinar with Ed Hurvitz MD

(57:13)

The *OFFICIAL* 2023 Toyota Prius Buying Guide - LE vs XLE vs LTD

(12:20)

Hormone Receptor-Positive and HER2-Positive Breast Cancer: A Medical Update

(1:8:15)

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

(20:25)

Medical Update: HER2-Positive Metastatic Breast Cancer

(19:38)

Dr. Hurvitz on the Clinical Use of Biosimilars in Oncology

(58)

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

(3:20)

Dr. Hurvitz on neoMONARCH Trial for HR+ Breast Cancer

(2:)

Dr. Hurvitz on Treatment Hypotheses for TNBC

(2:)

Dr. Hurvitz on Reducing Potential Exposure to COVID-19

(1:35)

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

(1:26)

Dr. Hurvitz on the Future of the Treatment of TNBC

(2:16)

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

(1:20)

Dr. Hurvitz on Biosimilars in Breast Cancer

(1:46)

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer

(1:58)

Dr. Hurvitz on the Need for Additional Research With Trastuzumab Deruxtecan in HER2+ Breast Cancer

(1:3)